Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Diversity|November 29, 2005
A convenient method to remove ruthenium byproducts from olefin metathesis reactions using polymer-bound triphenylphosphine oxide (TPPO)KyoungLang Haack, Yu Mi Ahn, Gunda I Georg
The Journal of Organic Chemistry|October 2, 2002
Synthetic studies with 13-deoxybaccatin IIIYu Mi Ahn, David G Vander Velde, Gunda I Georg
The Journal of Organic Chemistry|December 20, 2003
Formal total synthesis of (+)-salicylihalamides A and B: a combined chiral pool and RCM strategyKyoungLang Yang, Burchelle Blackman, Wibke Diederich, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry|November 25, 2006
Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analoguesYu Mi Ahn, Lakshminarayana Vogeti, Chun-Jing Liu, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
Molecular Cancer Therapeutics|August 20, 2015
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Bryan D Smith, Michael D Kaufman, Cynthia B Leary, et al.
Cancer Cell|April 13, 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Wayne W Chan, Scott C Wise, Michael D Kaufman, et al.
Pageof 2